Resistance of influenza A viruses to neuraminidase inhibitors can arise through mutations in the neuraminidase (NA) gene. We show here that a Q136K mutation in the NA of the 2009 pandemic H1N1 virus confers a high degree of resistance to zanamivir. Resistance is accompanied by reduced numbers of NA molecules in viral particles and reduced intrinsic enzymatic activity of mutant NA. Interestingly, the Q136K mutation strongly impairs viral fitness in the guinea pig transmission model. N euraminidase (NA) inhibitors, such as oseltamivir and zanamivir, are the most commonly used antiviral drugs for the treatment of severe infections with influenza A virus (FLUAV). Oseltamivir is available only for oral intake (1), whereas zanamivir may be inhaled or given intravenously (2, 3). While oseltamivir resistance has been studied extensively in seasonal H1N1 (sH1N1) (4-7) and pandemic H1N1 (pH1N1) (7-11) FLUAV strains, there are only a few reports of zanamivir resistance. A Q136K mutation in the viral neuraminidase was shown to confer zanamivir resistance in seasonal H1N1 virus strains (12, 13 ). An I223R mutation in the NA of a clinical pH1N1 isolate was reported to confer resistance to both oseltamivir and zanamivir (14, 15) . Both mutant viruses retained good transmissibility in the ferret transmission model (12, 15). Further, E119G or E119V mutations introduced by reverse genetics into the NA of a Canadian pH1N1 virus isolate were shown to confer multidrug resistance. However, both mutants exhibited severely compromised fitness (16). To date, there are no reports on NA mutations in the background of pH1N1 which would solely confer a high degree of resistance to zanamivir. Here, we investigated the potential of the pH1N1 strain A/Hansa Hamburg/01/2009 (identical to A/Hamburg/05/2009; GenBank accession numbers HQ111361 to HQ111368) to acquire zanamivir resistance.
N euraminidase (NA) inhibitors, such as oseltamivir and zanamivir, are the most commonly used antiviral drugs for the treatment of severe infections with influenza A virus (FLUAV). Oseltamivir is available only for oral intake (1), whereas zanamivir may be inhaled or given intravenously (2, 3) . While oseltamivir resistance has been studied extensively in seasonal H1N1 (sH1N1) (4-7) and pandemic H1N1 (pH1N1) (7-11) FLUAV strains, there are only a few reports of zanamivir resistance. A Q136K mutation in the viral neuraminidase was shown to confer zanamivir resistance in seasonal H1N1 virus strains (12, 13 ). An I223R mutation in the NA of a clinical pH1N1 isolate was reported to confer resistance to both oseltamivir and zanamivir (14, 15) . Both mutant viruses retained good transmissibility in the ferret transmission model (12, 15) . Further, E119G or E119V mutations introduced by reverse genetics into the NA of a Canadian pH1N1 virus isolate were shown to confer multidrug resistance. However, both mutants exhibited severely compromised fitness (16) . To date, there are no reports on NA mutations in the background of pH1N1 which would solely confer a high degree of resistance to zanamivir. Here, we investigated the potential of the pH1N1 strain A/Hansa Hamburg/01/2009 (identical to A/Hamburg/05/2009; GenBank accession numbers HQ111361 to HQ111368) to acquire zanamivir resistance.
The virus was subjected to 11 serial passages on Madin-Darby canine kidney (MDCK) cells in the presence of escalating concentrations of zanamivir starting from 1 nM up to 2 mM in the final passage. Zanamivir resistance of the passaged viruses was determined by the NA-Star assay (Applied Biosystems) which measures neuraminidase activity with a defined substrate (17) . The 50% inhibitory concentration (IC 50 ) values of zanamivir started to rise at passage 8 and reached a value of ϳ5 nM at passage 11 (Fig. 1A) . Sequencing of plaque-purified viruses from passage 11 revealed a glutamine-to-lysine mutation at amino acid position 136 of NA (Q136K). This mutation, as well as the well-described H275Y oseltamivir resistance mutation in NA, was introduced into the wild-type virus using reverse genetics. We found that the virus carrying the Q136K mutation exhibited an 86-fold increase in the IC 50 for zanamivir compared to the wild-type virus (Fig. 1B) but remained sensitive to oseltamivir carboxylic acid (TRC Inc., North York, Canada). In agreement with previous results (11), the H275Y mutant virus exhibited a high degree of resistance to oseltamivir but remained susceptible to zanamivir (Fig. 1B and C) . A virus simultaneously carrying both NA mutations (Q136K-H275Y) exhibited increased IC 50 s for zanamivir and oseltamivir ( Fig. 1B and C) , although the extent of resistance was less pronounced than in the viruses with single mutations.
On standard MDCK cells, all mutant viruses showed similar growth kinetics ( Fig. 2A) . In contrast, the Q136K single mutant virus and the Q136K-H275Y double mutant virus were severely compromised on MDCK-SIAT1 cells (18) that overexpress an ␣-2-6 sialyltransferase, which results in an enhanced proportion of surface sialic acids being in the ␣-2-6-linked conformation rather than the ␣-2-3-linked conformation (Fig. 2B ). These differences were confirmed in plaque assays which showed that viruses carrying the Q136K mutation had markedly reduced plaque size in MDCK-SIAT1 cells, but not in standard MDCK cells (data not shown). Using the guinea pig transmission model, we examined whether the Q136K mutation had an impact on viral transmissibility. To do this, four guinea pigs were inoculated intranasally with 10 4 focus-forming units (FFU) of the Q136K mutant virus. One day later, four naïve guinea pigs were contact exposed to the inoculated animals. Viral titers in nasal washes of all animals were determined by plaque assay on MDCK cells. The zanamivirresistant Q136K mutant virus reached only very low titers in nasal washings of inoculated animals, and the virus was not transmitted to naïve animals by contact exposure (Fig. 2C ). Under such experimental conditions, wild-type virus was readily transmitted (Fig. 2D) . These data suggest that the Q136K mutation markedly decreases viral fitness in vitro and in vivo.
Mutations in the NA gene might confer decreased enzymatic activity, which would compromise virus replication in cells expressing high levels of ␣-2-6-linked sialic acids and therefore might have an impact on virus transmission (5, (19) (20) (21) . Alternatively, incorporation of NA into the envelopes of budding viral particles may be reduced. To distinguish between these possibilities, we measured NA levels in viral particles purified from cell culture supernatants by polyethylene glycol (PEG) precipitation (22) . Viral nucleoprotein (NP) and NA levels were determined by Western blotting using NP-and NAspecific antisera (23) (Fig. 3A) , and NA/NP ratios were calculated for wild-type and mutant viruses by the Odyssey Fc imager system (Li-Cor Biosciences). The NA/NP ratio of mutant virus carrying the Q136K mutation was 3-to 4-fold lower than that of wild-type virus (P Ͻ 0.05), indicating that this mutation reduced the level of NA in viral particles (Fig. 3B) . In contrast, the NA H275Y mutation did not appear to significantly reduce NA levels in particles (Fig. 3B) . The specific activity of NA derived from the different viruses was determined using the NA-Star activity assay. Equal amounts of NA were analyzed using information from NA quantification by Western blotting. We found that NA carrying the Q136K mutation exhibited about 2-fold-lower enzymatic activity with the NA-Star chemiluminescent substrate compared to NA of wild-type vi- rus (Fig. 3C) . NA carrying the H275Y mutation alone or in combination with Q136K showed about 5-fold-lower enzymatic activity (Fig. 3C) .
Oseltamivir resistance has become widespread in sH1N1 (24-27) and was described in more than 400 cases of pH1N1 infections up to April 2011 (28) . Moreover, oseltamivir has been associated with neuropsychiatric side effects in pediatric settings primarily in Japan, emphasizing the need for alternative antiviral agents (29) . To date, the intravenous formulation of zanamivir, which is in phase III clinical development, has been used in cases of oseltamivir resistance in pediatric and intensive care patients (3, 30, 31) . In order to optimize therapy in the future, detection and characterization of mutations that confer zanamivir resistance is important. In this study, pH1N1 acquired a Q136K mutation in NA under vigorous selective pressure with zanamivir in cell culture. This is in contrast to a previous study, in which no high-level resistance to zanamivir was observed after serial passaging of a pH1N1 virus in the presence of this compound (32) . The Q136K mutation in NA was previously detected in a small number of sH1N1 isolates grown in MDCK cells. Since the mutants outgrew the wild-type viruses in MDCK cells and since Q136K subpopulations were not found in the original patient samples, it remains unclear whether this mutation in NA may occur only during virus growth in MDCK cells (12, 13) . In any case, sH1N1 strains carrying the Q136K mutation transmitted efficiently in the ferret model (12) .
In our study, the Q136K mutation did not alter the growth kinetics of a pH1N1 strain in conventional MDCK cells, but viral fitness was dramatically reduced in MDCK-SIAT1 cells as well as in the guinea pig transmission model. Amino acid Q136 is located in the periphery of the neuraminic acid binding site of the NA protein. The Q136K mutation was proposed to alter interactions with R156 and D151, thereby disrupting hydrogen bonds between D151 and zanamivir (12) . As the structure of zanamivir closely resembles that of natural N-acetyl neuraminic acid (33, 34) , it was proposed that NA mutations that prevent zanamivir binding might strongly alter the substrate binding properties of NA and thus result in loss of enzymatic activity (35) (36) (37) . We found that the Q136K mutation not only reduced the enzymatic activity of NA but also reduced NA levels in viral particles, which readily explains the attenuated phenotype of zanamivir-resistant viruses carrying the Q136K mutation.
The effect of the NA-H275Y mutation on fitness of pandemic H1N1 viruses varied considerably in published studies (7, 28) . In our study, the H275Y mutation alone did not negatively affect viral replication in MDCK-SIAT1 cells. However, when introduced together with the Q136K mutation, the H275Y mutation had a pronounced negative effect on virus growth. These various findings suggest that the fitness cost of the H275Y mutation depends heavily on the genetic makeup of the virus.
Taken together, the results presented here suggest that it is rather unlikely that zanamivir-resistant variants of pH1N1 carrying the Q136K mutations will emerge in clinical settings, even if oseltamivir-resistant H275Y variants should become widespread in the human population. 
